NCT07192237View on ClinicalTrials.gov

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 27, 2026

Primary Completion Date

October 12, 2030

Study Completion Date

October 12, 2032

Conditions
Phase 2 StudyBlinatumomabAcute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

Given by IV

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER